TSHA

Taysha Gene Therapies, Inc. Common Stock

4.97

USD

TSHA Earnings Reports

Positive Surprise Ratio

TSHA beat 10 of 21 last estimates.

48%

Next Report

Date of Next Report

Feb 24, 2026

Estimate for Q4 25 (Revenue/ EPS)

$2.10M

-$0.09

Implied change from Q3 25 (Revenue/ EPS)

Implied change from Q4 24 (Revenue/ EPS)

+3.95%

+28.57%

Taysha Gene Therapies, Inc. Common Stock earnings per share and revenue

On Nov 04, 2025, TSHA reported earnings of -0.09 USD per share (EPS) for Q3 25, Inline the estimate of -0.09 USD, resulting in a 0.00% surprise. Revenue reached --, compared to an expected 1.41 million, with a -100.00% difference. The market reacted with a -4.26% price change (close before vs. close after earnings).

Looking ahead to Q4 25, 15 analysts forecast an EPS of -0.09 USD, with revenue projected to reach 2.10 million USD, implying an increase of 0.00% EPS, and -- of --% in Revenue from the last quarter.

FAQ

What were Taysha Gene Therapies, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?

For Q3 2025, Taysha Gene Therapies, Inc. Common Stock reported EPS of -$0.09, missing estimates by 0%, and revenue of $0.00, -100% below expectations.

How did the market react to Taysha Gene Therapies, Inc. Common Stock's Q3 2025 earnings?

The stock price moved down -4.26%, changed from $4.46 before the earnings release to $4.27 the day after.

When is Taysha Gene Therapies, Inc. Common Stock expected to report next?

The next earning report is scheduled for Feb 24, 2026.

What are the forecasts for Taysha Gene Therapies, Inc. Common Stock's next earnings report?

Based on 15 analysts, Taysha Gene Therapies, Inc. Common Stock is expected to report EPS of -$0.09 and revenue of $2.10M for Q4 2025.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.